GI and Practice News

Clues Found to Aspirin’s Benefit in Colon Cancer

Aspirin’s survival benefit in colon cancer correlated with the drug’s antiplatelet activity but was not associated with a common tumor mutation or an enzyme linked to cancer etiology and pathogenesis, an analysis of 1,000 tumor samples showed. Low-dose aspirin after colon cancer diagnosis was associated with 47% better survival in patients whose tumors expressed human leukocyte antigen class I (HLA-I, a marker of platelet activation and aggregation, in addition to immunologic activity). Aspirin use did not correlate with PI3KA mutation or expression of cyclooxygenase-2 (COX-2).

NOTICE: Meadowbrook Endoscopy does not monitor or endorse the news feed presented above. This news is here for your information and entertainment only. You read and link to these third party content at your own risk.